According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.5	28.09.2024	9839712-00009	Date of first issue: 13.10.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Moxifloxacin Solid Formulation
1.2	Relevant identified uses of th	ne s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture		Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD 120 Moorgate EC2M 6UR London, United Kingdom
	Telephone	:	+44 (0) 2081548000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Acute toxicity, Category 4 Eye irritation, Category 2 Reproductive toxicity, Category 2 Specific target organ toxicity - repeated exposure, Category 2 H302: Harmful if swallowed.H319: Causes serious eye irritation.H361d: Suspected of damaging the unborn child.H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Moxifloxacin Solid Formulation

Version 3.5	Revision Date: 28.09.2024	SDS Numbe 9839712-00	
Hazard pictograms			
Signa	l word	: Warning	•
Haza	rd statements	: H302 H319 H361d H373	Harmful if swallowed. Causes serious eye irritation. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.
Preca	utionary statements	: Preventio P201 P270 P280	Don: Obtain special instructions before use. Do not eat, drink or smoke when using this prod- uct. Wear protective gloves/ protective clothing/ eye protection/ face protection.
		Respons P301 + P P308 + P P337 + P	 312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth. 313 IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label: Moxifloxacin HCL

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 2; H373 (Liver)	>= 40 - <= 70
Substances with a workplace exposure limit :			
Cellulose	9004-34-6		>= 10 - <= 30



Moxifloxacin Solid Formulation

Version 3.5	Revision Date: 28.09.2024	SDS Number: 9839712-00009	Date of last issue: 06.04.2024 Date of first issue: 13.10.2021	-
		232-674-9		
Eor e	valenation of abbrevia	232-674-9		

SECTION 4: First aid measures

4.1 Description of first aid measures General advice In the case of accident or if you feel unwell, seek medical ad-: vice immediately. When symptoms persist or in all cases of doubt seek medical advice. Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). If inhaled : If inhaled, remove to fresh air. Get medical attention. In case of skin contact In case of contact, immediately flush skin with soap and plenty : of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. In case of contact, immediately flush eyes with plenty of water In case of eye contact : for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention. If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person. 4.2 Most important symptoms and effects, both acute and delayed : Harmful if swallowed. Risks Causes serious eye irritation. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. 4.3 Indication of any immediate medical attention and special treatment needed Treatment : Treat symptomatically and supportively.



Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.5	28.09.2024	9839712-00009	Date of first issue: 13.10.2021

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
5.2 Special hazards arising from		e substance or mixture

Specific hazards during fire- fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides
5.3 Advice for firefighters		
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

on resonar pressations, protect		e equipment and emergency procedures
Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. If spillage enters rivers or watercourses, inform the Environ- ment Agency (emergency telephone number 0800 807060).

6.3 Methods and material for containment and cleaning up

Methods for cleaning up	:	Sweep up or vacuum up spillage and collect in suitable con- tainer for disposal.
		Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items



Moxifloxacin Solid Formulation

Version 3.5	Revision Date: 28.09.2024	SDS Number: 9839712-00009	Date of last issue: 06.04.2024 Date of first issue: 13.10.2021
		mine which re Sections 13 a	he cleanup of releases. You will need to deter- gulations are applicable. nd 15 of this SDS provide information regarding or national requirements.
6.4 Refer	ence to other sections		
See section	ons: 7, 8, 11, 12 and 13.		
SECTIO	N 7: Handling and st	orage	
	5	0	
7.1 Preca	utions for safe handlir	ng	
Tech	nical measures		ing measures under EXPOSURE
Loca	I/Total ventilation		PERSONAL PROTECTION section. adequate ventilation.
	ce on safe handling	: Do not breath	e dust, fume, gas, mist, vapours or spray.
		Do not swallo	
		Do not get in Avoid prolong	eyes. ed or repeated contact with skin.
			proughly after handling.
			ordance with good industrial hygiene and safety ed on the results of the workplace exposure as-
		sessment	a on the results of the workplace exposure as
		-	ink or smoke when using this product.
		Take care to environment.	prevent spills, waste and minimize release to the
Hygie	ene measures	: If exposure to	chemical is likely during typical use, provide eye
			ms and safety showers close to the working
			using do not eat, drink or smoke. Wash contami- before re-use.
			operation of a facility should include review of

engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers	:	Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.
Advice on common storage	:	Do not store with the following product types: Strong oxidizing agents
7.3 Specific end use(s)		

Specific use(s)	: No data available
-----------------	---------------------

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Moxifloxacin Solid Formulation

Vers 3.5	sion Revision E 28.09.202				
	Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
	Moxifloxacin HCL	186826-86- 8	TWA	1000 µg/m3 (OEB 1)	Internal
	Cellulose	9004-34-6	TWA (inhalable dust)	10 mg/m3	GB EH40
			TWA (Respirable dust)	4 mg/m3	GB EH40
			STEL (inhalable dust)	20 mg/m3	GB EH40

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection Material	:	Chemical-resistant gloves
Skin and body protection Respiratory protection	:	Work uniform or laboratory coat. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to BS EN 143
Filter type	:	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	:	solid pink odourless No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	No data available
range Flash point	:	Not applicable
Evaporation rate	:	No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Moxifloxacin Solid Formulation

Ver 3.5	sion	Revision Date: 28.09.2024	-	S Number: 39712-00009	Date of last issue: 06.04.2024 Date of first issue: 13.10.2021
	Flamm	ability (solid, gas)		Not classified as	a flammability hazard
	Fidititi	ability (solid, gas)	•	Not classified as	
		explosion limit / Upper ability limit	:	No data available	9
		explosion limit / Lower ability limit	:	No data available	9
	Vapou	rpressure	:	No data available	9
	Relativ	e vapour density	:	No data available	9
	Relativ	e density	:	No data available	9
	Density	/	:	No data available	9
		ter solubility n coefficient: n-	:	No data available No data available	
	Auto-ig	nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	Viscosi Visc	ity cosity, kinematic	:	No data available	9
	Explos	ive properties	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
9.2	Other ir	nformation			
	Flamm	ability (liquids)	:	No data available	e
	Molecu	ılar weight	:	Not applicable	
	Particle	e size	:	No data available	9

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Moxifloxacin Solid Formulation

Versi 3.5	on	Revision Date: 28.09.2024		S Number: 39712-00009	Date of last issue: 06.04.2024 Date of first issue: 13.10.2021
10.4	Conditi	ions to avoid			
(Conditio	ons to avoid	:	None known.	
10.5	Incomp	patible materials			
	-	ls to avoid	:	Oxidizing agents	
10.6	Hazard	ous decomposition p	orod	ucts	
		ardous decomposition			
SEC	TION 1	11: Toxicological in	forr	mation	
11.1	Informa	ation on toxicological	l eff	ects	
I	Informa	tion on likely routes of		Skin contact	
(exposu	re		Ingestion Eye contact	
	Acute t Harmful	oxicity I if swallowed.			
-	Produc				
/	Acute o	ral toxicity	:	Acute toxicity estin Method: Calculation	
<u>(</u>	Compo	nents:			
I	Moxiflo	oxacin HCL:			
1	Acute o	ral toxicity	:	LD50 (Rat): 1,320	mg/kg
				LD50 (Mouse): > 4	435 mg/kg
				LD50 (Monkey): 1	,500 mg/kg
(Cellulo	se:			
/	Acute o	ral toxicity	:	LD50 (Rat): > 5,00	00 mg/kg
,	Acute ir	nhalation toxicity	:	LC50 (Rat): > 5.8 Exposure time: 4 I Test atmosphere:	า
/	Acute d	ermal toxicity	:	LD50 (Rabbit): > 2	2,000 mg/kg
		orrosion/irritation ssified based on availal	ble i	nformation.	
<u>(</u>	Compo	nents:			
I	Moxiflo	oxacin HCL:			
	Species Result	3	:	Rabbit No skin irritation	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.5	28.09.2024	9839712-00009	Date of first issue: 13.10.2021

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Moxifloxacin HCL:

Species	:	Rabbit
Result	:	Moderate eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:

Moxifloxacin HCL:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: positive
		Test Type: Chromosome aberration test in vitro Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
		Test Type: in vitro micronucleus test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Application Route: Oral Result: negative
Cellulose:		
Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Moxifloxacin Solid Formulation

Versior 3.5		Revision Date: 28.09.2024		S Number: 39712-00009	Date of last issue: 06.04.2024 Date of first issue: 13.10.2021
				Result: negative	
No		genicity iified based on availa ents:	ble	information.	
Sp Ap E>	ellulos pecies pplicatio xposure esult	on Route	: : :	Rat Ingestion 72 weeks negative	
	-	i ctive toxicity ed of damaging the ui	nboi	n child.	
<u>Co</u>	ompor	ents:			
M	oxiflox	acin HCL:			
Ef	ffects o	n fertility	:	Species: Rat Application Route	500 mg/kg body weight
	ffects o ent	n foetal develop-	:	Species: Monkey Application Route	o-foetal development : Oral oxicity: NOAEL: 10 mg/kg body weight
				Species: Rabbit Application Route	o-foetal development : Intravenous injection oxicity: LOAEL: 20 mg/kg body weight tal malformations
	eprodu essmen	ctive toxicity - As- t	:	Some evidence of animal experimen	f adverse effects on development, based on ts.
Ce	ellulos	e:			
		n fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion
	ffects o ient	n foetal develop-	:	Test Type: Fertility Species: Rat Application Route Result: negative	y/early embryonic development : Ingestion

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.5	28.09.2024	9839712-00009	Date of first issue: 13.10.2021

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Moxifloxacin HCL:

:	Liver May cause damage to organs through prolonged or repeated exposure.
	exposure.
	:

Repeated dose toxicity

Components:

Moxifloxacin HCL: Species LOAEL Application Route Exposure time	:	Rat 100 mg/kg Oral 4 Weeks
Species NOAEL Application Route Exposure time Target Organs Symptoms	· · ·	Rat 100 mg/kg Oral 13 Weeks Liver Liver disorders
Species NOAEL Application Route Exposure time Target Organs Symptoms	· · · ·	Rat 20 mg/kg Oral 6 Months Liver Liver disorders
Species NOAEL Application Route Exposure time Symptoms	:	Monkey 50 mg/kg Oral 4 Weeks No adverse effects
Species NOAEL Application Route Exposure time Target Organs Symptoms	· · ·	Monkey 15 mg/kg Oral 13 Weeks Gastrointestinal tract Vomiting
Species Application Route Exposure time	:	Monkey Oral 26 Weeks

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Moxifloxacin Solid Formulation

Version 3.5	Revision Date: 28.09.2024		Date of last issue: 06.04.2024 Date of first issue: 13.10.2021
Targe Symp	et Organs otoms	: Liver : Liver disorders	
Cellu Speci NOAE	es	: Rat : >= 9,000 mg/kg	
	cation Route sure time	: Ingestion : 90 Days	
-	ration toxicity lassified based on ava	able information.	
Expe	rience with human ex	posure	
<u>Com</u>	oonents:		
Moxi	floxacin HCL:		
Inges	tion		a, Abdominal pain, Headache, Dizziness, stem effects, joint pain
SECTION	12: Ecological inf	rmation	
2.1 Toxic	city		
Com	ponents:		
Cellu	lose:		
Toxic	ity to fish	Exposure time: 48	bes (Japanese medaka)): > 100 mg/l h n data from similar materials
12.2 Persi	stence and degradal	lity	
Com	oonents:		
Cellu Biode	lose: gradability	: Result: Readily bio	degradable.
12.3 Bioa	ccumulative potentia		
No da	ata available		
12.4 Mobi	•		
1 2.4 Mobi No da	ata available lity in soil	ssessment	
1 2.4 Mobi No da	ata available lity in soil ata available ilts of PBT and vPvB	ssessment	
12.4 Mobi No da 12.5 Resu <u>Prod</u> e	ata available lity in soil ata available ilts of PBT and vPvB	: This substance/mix to be either persist	ture contains no components considered ent, bioaccumulative and toxic (PBT), or I very bioaccumulative (vPvB) at levels of



Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.5	28.09.2024	9839712-00009	Date of first issue: 13.10.2021

12.6 Other adverse effects

Product:

Endocrine disrupting poten- tial	:	This substance/mixture does not contain components consid- ered to have endocrine disrupting properties for environment according to UK REACH Article 57(f).
-------------------------------------	---	--

SECTION 13: Disposal considerations

13.1 Waste treatment methods	
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

	ADN	:	Not regulated as a dangerous good
	ADR	:	Not regulated as a dangerous good
	RID	:	Not regulated as a dangerous good
	IMDG	:	Not regulated as a dangerous good
	ΙΑΤΑ	:	Not regulated as a dangerous good
14.	2 UN proper shipping name		
	ADN	:	Not regulated as a dangerous good
	ADR	:	Not regulated as a dangerous good
	RID	:	Not regulated as a dangerous good
	IMDG	:	Not regulated as a dangerous good
	ΙΑΤΑ	:	Not regulated as a dangerous good
14.:	3 Transport hazard class(es)		
	ADN	:	Not regulated as a dangerous good
	ADR	:	Not regulated as a dangerous good
	RID	:	Not regulated as a dangerous good
	IMDG	:	Not regulated as a dangerous good
	ΙΑΤΑ	:	Not regulated as a dangerous good

UK REACH Regulations SI 2019/758

According to REACH Regulation (EC) No 1907/2006, as amended by



Moxifloxacin Solid Formulation

Version 3.5	Revision Date: 28.09.2024	SDS Number: 9839712-00009	Date of last issue: 06.04.2024 Date of first issue: 13.10.2021			
14.4 Pack	14.4 Packing group					
ADN		: Not regulated a	as a dangerous good			
ADR		: Not regulated a	as a dangerous good			
RID		: Not regulated a	as a dangerous good			
IMDG		: Not regulated a	as a dangerous good			
ΙΑΤΑ	(Cargo)	: Not regulated a	as a dangerous good			
ΙΑΤΑ	(Passenger)	: Not regulated a	as a dangerous good			
14.5 Environmental hazards						
Not regulated as a dangerous good						
14.6 Special precautions for user Not applicable						
14.7 Transport in bulk according to Annex II of Marpol and the IBC Code						

: Not applicable for product as supplied.

SECTION 15: Regulatory information

Remarks

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17)	:	Not applicable
UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation	:	Not applicable
The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Brit-	:	Not applicable
ain) Regulation (EC) on substances that deplete the ozone	:	Not applicable
layer UK REACH List of substances subject to authorisation	:	Not applicable
(Annex XIV) GB Export and import of hazardous chemicals - Prior	:	Not applicable
Informed Consent (PIC) Regulation Control of Major Accident Hazards Regulations 2015 (CC Not applicable	DMA	. H)

Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

The components of this product are reported in the following inventories:

AICS : not determined



Moxifloxacin Solid Formulation

Version 3.5	Revision Date: 28.09.2024	SDS Number: 9839712-00009	Date of last issue: 06.04.2024 Date of first issue: 13.10.2021
DSL		: not determined	
DSL		. not determined	
IECS	С	: not determined	
A Chemic	nical safety assessm al Safety Assessment	has not been carried o	ut.
Other	- information		anges have been made to the previous version in the body of this document by two vertical
Full t	ext of H-Statements		
H302		: Harmful if swalle	owed.
H319		: Causes serious	•
H361	-	•	amaging the unborn child.
H373		: May cause dam exposure.	age to organs through prolonged or repeated
Full t	ext of other abbrevia	tions	
Acute	e Tox.	: Acute toxicity	

Acute Tox.	:	Acute toxicity
Eye Irrit.	:	Eye irritation
Repr.	:	Reproductive toxicity
STOT RE	:	Specific target organ toxicity - repeated exposure
GB EH40	:	UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA	:	Long-term exposure limit (8-hour TWA reference period)
GB EH40 / STEL	:	Short-term exposure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office



Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.5	28.09.2024	9839712-00009	Date of first issue: 13.10.2021

of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet	:		data from raw material SDSs, OECD sults and European Chemicals Agen- u/
Classification of the mixtur	e:		Classification procedure:
Acute Tox. 4	H3()2	Calculation method
Eye Irrit. 2	H3 ⁻	19	Calculation method
Repr. 2	H36	61d	Calculation method
STOT RE 2	H37	73	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN